Orthocell Ltd (AU:OCC) has released an update.
Orthocell Ltd has secured $17 million through an institutional placement to fund the launch of its Remplir™ product in the lucrative US market and expand globally. This strategic move brings in both new and existing investors, positioning the regenerative medicine company for significant growth. With a strong cash reserve, Orthocell is set to enhance manufacturing efficiency and accelerate its market expansion strategy.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.